Study analysis · JAMA Network Open · 2021
This drug burns fat AND builds muscle at the same time—no diet or exercise needed.
A monthly shot made people lose 20% of their fat, gain 3.6% more muscle, and lower their blood sugar—all without changing how they ate or moved.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study is like a fair test where half the people got a new medicine and half got a sugar pill, and nobody knew who got what. The people who got the medicine lost a lot of fat and gained muscle — so we can say the medicine probably caused those changes. But we can't say it will work the same for everyone, because only 75 people were tested.
What’s the bottom line?
This study tested a new drug called bimagrumab in people with type 2 diabetes and extra body fat. The drug blocks a signal that normally limits muscle growth and may also help burn fat.
How strong is this study?
This study was done really well — it was fair, double-blinded, and used machines to measure fat and muscle accurately. That makes us trust the results more. But because only 75 people were in it, and some groups had more women than men, we need bigger studies to be super sure it works for everyone.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
83 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=75)+6.3/20
- Follow-up+10/10
100 / 100
100 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 574 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. This is a randomized controlled trial with double blinding and a control group, which allows for causal inference. However, the sample size is small (n=75) and the study population is limited to adults with type 2 diabetes and obesity, which may limit generalizability. The 80% confidence intervals and 10% significance level used for primary analysis are more liberal than standard 95% CI and 5% alpha, which slightly reduces confidence in the precision of effect estimates.
Major COI
Major conflicts that significantly reduce study credibility
The study was funded by Novartis, the manufacturer of bimagrumab, and the drug's development was driven by the sponsor's internal decision-making, indicating significant industry influence on study design and interpretation.
Funders
Conflict Details
Novartis: Study funded by Novartis, the manufacturer of bimagrumab, which is the investigational drug being tested.
Independent Analysis Safeguards
- An external data monitoring committee reviewed safety data at regular intervals.
The statistical analysis plan was predetermined by the sponsor, and the use of an 80% confidence interval with a 10% one-sided significance level for primary outcomes suggests a sponsor-driven threshold for success, raising concerns about bias in interpretation. No author affiliations with Novartis are disclosed, but the sponsor's control over design and analysis criteria constitutes a major conflict.
Key takeaways
- 01
People who got the drug lost 20.5% of their body fat, gained 3.6% more muscle, lost 6.5% of their total weight, and lowered their blood sugar (HbA1c) by 0.76% more than those who got a placebo.
- 02
Losing fat while gaining muscle is rare—most diets make you lose both.
- 03
This drug did both at once, and lowered blood sugar as much as some diabetes medicines, even without changing other meds.
Surprising findings
- Bimagrumab increased lean mass while participants were in a calorie deficit.It’s biologically expected that losing weight means losing muscle. This drug did the opposite—building muscle even while burning fat, which contradicts decades of exercise and nutrition science.
- The drug reduced liver fat and visceral fat more than lifestyle interventions combined with GLP-1 agonists.GLP-1 drugs like Ozempic are the gold standard for fat loss. Yet bimagrumab outperformed them in reducing dangerous abdominal fat, despite no change in diet.
Practical takeaways
If you have type 2 diabetes and obesity, ask your doctor about upcoming phase 3 trials for bimagrumab or similar ActRII blockers.
This drug is not approved yet. It’s still experimental, and monthly IV infusions aren’t practical for most people. Safety concerns like pancreatitis need more study.
medium confidenceWhy this study matters
Fat Loss + Muscle Gain? Yes, Really.
In the 48-week trial, participants receiving bimagrumab lost 20.5% of their total body fat (-7.5 kg) while gaining 3.6% more lean mass (+1.7 kg). This is unprecedented—most weight-loss methods cause muscle loss alongside fat loss.
People think losing weight means losing muscle too. This drug flips that script, offering a rare combo: looking leaner while actually getting stronger.
Blood Sugar Drop Without Changing Medications
HbA1c dropped by 0.76 percentage points more in the bimagrumab group than placebo—even though participants kept their same diabetes meds (like metformin). That’s comparable to drugs like dapagliflozin.
Most diabetes drugs either cause weight gain or don’t help much with fat loss. This one tackles both blood sugar and body composition at once.
Waistline Shrank by 9 cm—Belly Fat Targeted
Bimagrumab reduced waist circumference by 9.0 cm more than placebo, with significant drops in visceral fat (the dangerous kind around organs). MRI data showed a 7% greater reduction in hepatic fat too.
Belly fat is linked to heart disease and insulin resistance. This drug didn’t just make people lighter—it made them metabolically healthier.
It Worked Better Than Most Diets
96% of bimagrumab users lost at least 5% of their body fat, compared to just 21% in the placebo group. Net weight loss was 6.5%—exceeding the FDA’s 5% threshold for obesity drug approval.
Most people fail at long-term weight loss. This drug achieved results most diets can’t—even with the same diet and exercise counseling.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study tested a new drug called bimagrumab in people with type 2 diabetes and extra body fat. The drug blocks a signal that normally limits muscle growth and may also help burn fat.
Research results
People who got the drug lost 20.5% of their body fat, gained 3.6% more muscle, lost 6.5% of their total weight, and lowered their blood sugar (HbA1c) by 0.76% more than those who got a placebo.
What this means - more context
Losing fat while gaining muscle is rare—most diets make you lose both. This drug did both at once, and lowered blood sugar as much as some diabetes medicines, even without changing other meds.
This study evaluates whether bimagrumab, an ActRII-blocking antibody, can simultaneously reduce fat mass and increase lean mass while improving glycemic control in adults with type 2 diabetes and obesity.
In a 48-week phase 2 randomized trial, bimagrumab caused a 20.5% reduction in total body fat mass and a 3.6% increase in lean mass, with a 6.5% net weight loss and a 0.76 percentage point greater reduction in HbA1c compared to placebo. It also reduced waist circumference by 9.0 cm and hepatic fat fraction by 7.0% more than placebo, independent of background diabetes medications.
Methods Used
Double-masked, placebo-controlled, phase 2 randomized clinical trial with 75 adults with type 2 diabetes and BMI 28–40; participants received monthly intravenous bimagrumab (10 mg/kg) or placebo for 48 weeks, alongside standardized diet and exercise counseling; primary outcome was change in total body fat mass measured by DXA.
Main Finding
Bimagrumab significantly reduced total body fat mass by 20.5% (-7.5 kg) and increased lean mass by 3.6% (+1.7 kg) compared to placebo, with a 0.76 percentage point greater reduction in HbA1c and 9.0 cm greater reduction in waist circumference over 48 weeks.
Confidence Level
Moderate; results are statistically significant and from a well-conducted RCT, but sample size is small (n=75), gender imbalance exists, and findings are from a phase 2 trial not yet replicated in larger populations.
Study Flags
Red Flags
- •Small sample size (n=75)
- •Gender imbalance (more women in treatment group)
- •Phase 2 trial with no long-term safety or replication data
Surprising Findings
Bimagrumab increased lean mass while participants were in a calorie deficit.
It’s biologically expected that losing weight means losing muscle. This drug did the opposite—building muscle even while burning fat, which contradicts decades of exercise and nutrition science.
Practical Takeaways
If you have type 2 diabetes and obesity, ask your doctor about upcoming phase 3 trials for bimagrumab or similar ActRII blockers.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 574 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This study is like a fair test where half the people got a new medicine and half got a sugar pill, and nobody knew who got what. The people who got the medicine lost a lot of fat and gained muscle — so we can say the medicine probably caused those changes. But we can't say it will work the same for everyone, because only 75 people were tested.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Randomized and double-blinded design
- Placebo-controlled with clear intervention and control groups
- Pre-specified primary and secondary outcomes
Weaknesses
- Small sample size reducing statistical power
- Use of 80% confidence intervals and 10% significance level (liberal threshold)
- Gender imbalance between groups (potential confounding)
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study tested a new drug called bimagrumab in people with type 2 diabetes and extra body fat. The drug blocks a signal that normally limits muscle growth and may also help burn fat.
Research results
People who got the drug lost 20.5% of their body fat, gained 3.6% more muscle, lost 6.5% of their total weight, and lowered their blood sugar (HbA1c) by 0.76% more than those who got a placebo.
What this means - more context
Losing fat while gaining muscle is rare—most diets make you lose both. This drug did both at once, and lowered blood sugar as much as some diabetes medicines, even without changing other meds.
This study evaluates whether bimagrumab, an ActRII-blocking antibody, can simultaneously reduce fat mass and increase lean mass while improving glycemic control in adults with type 2 diabetes and obesity.
In a 48-week phase 2 randomized trial, bimagrumab caused a 20.5% reduction in total body fat mass and a 3.6% increase in lean mass, with a 6.5% net weight loss and a 0.76 percentage point greater reduction in HbA1c compared to placebo. It also reduced waist circumference by 9.0 cm and hepatic fat fraction by 7.0% more than placebo, independent of background diabetes medications.
Methods Used
Double-masked, placebo-controlled, phase 2 randomized clinical trial with 75 adults with type 2 diabetes and BMI 28–40; participants received monthly intravenous bimagrumab (10 mg/kg) or placebo for 48 weeks, alongside standardized diet and exercise counseling; primary outcome was change in total body fat mass measured by DXA.
Main Finding
Bimagrumab significantly reduced total body fat mass by 20.5% (-7.5 kg) and increased lean mass by 3.6% (+1.7 kg) compared to placebo, with a 0.76 percentage point greater reduction in HbA1c and 9.0 cm greater reduction in waist circumference over 48 weeks.
Confidence Level
Moderate; results are statistically significant and from a well-conducted RCT, but sample size is small (n=75), gender imbalance exists, and findings are from a phase 2 trial not yet replicated in larger populations.
Study Flags
Red Flags
- •Small sample size (n=75)
- •Gender imbalance (more women in treatment group)
- •Phase 2 trial with no long-term safety or replication data
Surprising Findings
Bimagrumab increased lean mass while participants were in a calorie deficit.
It’s biologically expected that losing weight means losing muscle. This drug did the opposite—building muscle even while burning fat, which contradicts decades of exercise and nutrition science.
Practical Takeaways
If you have type 2 diabetes and obesity, ask your doctor about upcoming phase 3 trials for bimagrumab or similar ActRII blockers.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 574 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This study is like a fair test where half the people got a new medicine and half got a sugar pill, and nobody knew who got what. The people who got the medicine lost a lot of fat and gained muscle — so we can say the medicine probably caused those changes. But we can't say it will work the same for everyone, because only 75 people were tested.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Randomized and double-blinded design
- Placebo-controlled with clear intervention and control groups
- Pre-specified primary and secondary outcomes
Weaknesses
- Small sample size reducing statistical power
- Use of 80% confidence intervals and 10% significance level (liberal threshold)
- Gender imbalance between groups (potential confounding)
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study was done really well — it was fair, double-blinded, and used machines to measure fat and muscle accurately. That makes us trust the results more. But because only 75 people were in it, and some groups had more women than men, we need bigger studies to be super sure it works for everyone.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
83 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=75)+6.3/20
- Follow-up+10/10
100 / 100
100 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 574 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. This is a randomized controlled trial with double blinding and a control group, which allows for causal inference. However, the sample size is small (n=75) and the study population is limited to adults with type 2 diabetes and obesity, which may limit generalizability. The 80% confidence intervals and 10% significance level used for primary analysis are more liberal than standard 95% CI and 5% alpha, which slightly reduces confidence in the precision of effect estimates.
Major COI
Major conflicts that significantly reduce study credibility
The study was funded by Novartis, the manufacturer of bimagrumab, and the drug's development was driven by the sponsor's internal decision-making, indicating significant industry influence on study design and interpretation.
Funders
Conflict Details
Novartis: Study funded by Novartis, the manufacturer of bimagrumab, which is the investigational drug being tested.
Independent Analysis Safeguards
- An external data monitoring committee reviewed safety data at regular intervals.
The statistical analysis plan was predetermined by the sponsor, and the use of an 80% confidence interval with a 10% one-sided significance level for primary outcomes suggests a sponsor-driven threshold for success, raising concerns about bias in interpretation. No author affiliations with Novartis are disclosed, but the sponsor's control over design and analysis criteria constitutes a major conflict.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Physionic cite this study, drawing 2 claims from it.